IDEAS home Printed from https://ideas.repec.org/a/eee/csdana/v206y2025ics0167947325000064.html
   My bibliography  Save this article

A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients

Author

Listed:
  • Bilancia, Massimo
  • Solimando, Antonio Giovanni
  • Manca, Fabio
  • Vacca, Angelo
  • Ria, Roberto

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells, originating from B lymphocytes and accumulating within the bone marrow. The prevalence of MM has increased in industrialized countries, representing 1-1.8% of all cancers and 15% of hematologic malignancies. Immunotherapy has broadened therapeutic options for MM, offering treatments with generally improved efficacy and reduced toxicity compared to conventional therapies. Daratumumab, a monoclonal antibody recently granted regulatory approval, exemplifies this advancement, demonstrating improved patient outcomes. However, the substantial cost of daratumumab has significantly increased per-patient treatment expenditures. Consequently, the economic burden associated with this new class of therapies warrants careful evaluation of their cost-effectiveness. To address this, a six-state non-stationary Markov model was developed for cost-effectiveness analysis of immunotherapy in newly diagnosed MM patients and, more broadly, in the oncohematological patient population. This model aims to provide healthcare professionals and policymakers with actionable insights into cost-effective interventions, supporting informed decisions regarding optimal treatment strategies.

Suggested Citation

  • Bilancia, Massimo & Solimando, Antonio Giovanni & Manca, Fabio & Vacca, Angelo & Ria, Roberto, 2025. "A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients," Computational Statistics & Data Analysis, Elsevier, vol. 206(C).
  • Handle: RePEc:eee:csdana:v:206:y:2025:i:c:s0167947325000064
    DOI: 10.1016/j.csda.2025.108130
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0167947325000064
    Download Restriction: Full text for ScienceDirect subscribers only.

    File URL: https://libkey.io/10.1016/j.csda.2025.108130?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:csdana:v:206:y:2025:i:c:s0167947325000064. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/csda .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.